247 related articles for article (PubMed ID: 32201368)
1. Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity.
Nicolini A; Rossi G; Ferrari P; Carpi A
Semin Cancer Biol; 2022 Feb; 79():68-82. PubMed ID: 32201368
[TBL] [Abstract][Full Text] [Related]
2. Minimal Residual Disease, Metastasis and Immunity.
Badia-Ramentol J; Linares J; Gómez-Llonin A; Calon A
Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33498251
[TBL] [Abstract][Full Text] [Related]
3. Myeloid derived suppressor cells and the release of micro-metastases from dormancy.
Khadge S; Cole K; Talmadge JE
Clin Exp Metastasis; 2021 Jun; 38(3):279-293. PubMed ID: 34014424
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
Front Immunol; 2020; 11():585214. PubMed ID: 33613512
[TBL] [Abstract][Full Text] [Related]
5. Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities.
Ramamoorthi G; Kodumudi K; Gallen C; Zachariah NN; Basu A; Albert G; Beyer A; Snyder C; Wiener D; Costa RLB; Czerniecki BJ
Semin Cancer Biol; 2022 Jan; 78():78-89. PubMed ID: 33626407
[TBL] [Abstract][Full Text] [Related]
6. Role of myeloid-derived suppressor cells in metastasis.
Cole K; Pravoverov K; Talmadge JE
Cancer Metastasis Rev; 2021 Jun; 40(2):391-411. PubMed ID: 33411082
[TBL] [Abstract][Full Text] [Related]
7. Tumor dormancy: long-term survival in a hostile environment.
Quesnel B
Adv Exp Med Biol; 2013; 734():181-200. PubMed ID: 23143980
[TBL] [Abstract][Full Text] [Related]
8. Tumor dormancy and cancer stem cells: two sides of the same coin?
Kleffel S; Schatton T
Adv Exp Med Biol; 2013; 734():145-79. PubMed ID: 23143979
[TBL] [Abstract][Full Text] [Related]
9. Immune dysfunction, minimal residual disease and patient outcome in nonmetastatic cancer: could modulation of immune function improve outcome?
Murray NP
Future Oncol; 2021 May; 17(13):1571-1575. PubMed ID: 33626930
[No Abstract] [Full Text] [Related]
10. Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy.
Chesney JA; Mitchell RA; Yaddanapudi K
J Leukoc Biol; 2017 Sep; 102(3):727-740. PubMed ID: 28546500
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports.
Nicolini A; Ferrari P; Morganti R; Carpi A
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795079
[TBL] [Abstract][Full Text] [Related]
12. Role of myeloid-derived suppressor cells in tumor recurrence.
Cole K; Al-Kadhimi Z; Talmadge JE
Cancer Metastasis Rev; 2023 Mar; 42(1):113-142. PubMed ID: 36640224
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal cancer stem cells as targets for innovative immunotherapy.
Chivu-Economescu M; Necula LG; Matei L; Dragu DL; Neagu AI; Alexiu I; Bleotu C; Diaconu CC
World J Gastroenterol; 2020 Apr; 26(14):1580-1593. PubMed ID: 32327907
[TBL] [Abstract][Full Text] [Related]
14. A Nanoplatform to Amplify Apoptosis-to-Pyroptosis Immunotherapy via Immunomodulation of Myeloid-Derived Suppressor Cells.
Zhou S; Shang Q; Ji J; Luan Y
ACS Appl Mater Interfaces; 2021 Oct; 13(40):47407-47417. PubMed ID: 34597015
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer.
Toor SM; Elkord E
Immunol Cell Biol; 2018 Oct; 96(9):888-897. PubMed ID: 29635843
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic and Pluripotency Aspects of Disseminated Cancer Cells During Minimal Residual Disease.
Carlini MJ; Shrivastava N; Sosa MS
Adv Exp Med Biol; 2018; 1100():1-18. PubMed ID: 30411257
[TBL] [Abstract][Full Text] [Related]
17. Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells.
Payne KK; Keim RC; Graham L; Idowu MO; Wan W; Wang XY; Toor AA; Bear HD; Manjili MH
J Leukoc Biol; 2016 Sep; 100(3):625-35. PubMed ID: 26928306
[TBL] [Abstract][Full Text] [Related]
18. Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics.
Adah D; Hussain M; Qin L; Qin L; Zhang J; Chen X
Pharmacol Res; 2016 Aug; 110():25-34. PubMed ID: 27157248
[TBL] [Abstract][Full Text] [Related]
19. Interaction between the immune system and acute myeloid leukemia: A model incorporating promotion of regulatory T cell expansion by leukemic cells.
Nishiyama Y; Saikawa Y; Nishiyama N
Biosystems; 2018 Mar; 165():99-105. PubMed ID: 29408212
[TBL] [Abstract][Full Text] [Related]
20. Green propolis increases myeloid suppressor cells and CD4
Piñeros AR; de Lima MHF; Rodrigues T; Gembre AF; Bertolini TB; Fonseca MD; Berretta AA; Ramalho LNZ; Cunha FQ; Hori JI; Bonato VLD
J Ethnopharmacol; 2020 Apr; 252():112496. PubMed ID: 31870795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
